Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes
Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.
You may also be interested in...
A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
AbbVie has in-licensed Lupin’s MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor program for over $900m in potential milestone payments, bringing Christmas cheer for the Indian firm. The deal terms for the preclinical asset are rather striking.
An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.